The Freshfields team is being led by corporate partner Chris Mort

Freshfields Bruckhaus Deringer LLP (‘Freshfields’) has advised ConvaTec on its proposal to raise $1.8 billion through an IPO and listing on the London Stock Exchange. ConvaTec is a global medical products and technologies group which focusses on therapies for the management of chronic conditions.

The proposed IPO will serve as an opportunity for ConvaTec’s largest shareholders, Nordic Capital and Avista Capital Partners, as well as members of the management team, to realise part of their investment. ConvaTec has said it will use the net proceeds of the IPO primarily in the repayment of existing borrowings.

A global leader in the development, manufacturing and marketing of innovative medical products, ConvaTec’s four franchises provide devices used for advanced chronic and acute wound care, ostomy care, continence and critical care. The company also manufactures infusion devices used in the treatment of diabetes and other conditions. ConvaTec sells its products in more than 100 countries and has over 9,000 employees worldwide.

The Freshfields team is being led by corporate partner Chris Mort.